Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

velpatasvir

Gilead Sciences

Gilead and Achillion see 100% success rate in hep C trial

New combination treatment aims to compete in a rapidly evolving market for the disease

- PMLiVE

Non-profit calls to revoke Sovaldi’s European patent

Doctors of the World says Gilead is “abusing its patent” to impose unsustainable prices

- PMLiVE

Gilead to open London headquarters

Mayor Boris Johnson makes announcement as part of trip to Boston, US

- PMLiVE

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

- PMLiVE

US seeking price cuts for Medicare drugs

White House proposes allowing Medicare Part D to haggle with pharma companies for discounts

Gilead Sciences

Gilead cuts hepatitis C drug prices in Germany

Discount on Sovaldi and Harvoni follows similar agreement in France

- PMLiVE

Aetna picks Gilead’s hepatitis C drugs

Health insurance firm favours Sovaldi and Harvoni after negotiating discount

- PMLiVE

Janssen will cover cost of unsuccessful hepatitis C treatment

NHS England will only have to pay for Olysio if patient clears virus

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

EC clears AbbVie’s oral hepatitis C regimen

Viekirax and Exviera offer competition to Gilead’s Sovaldi

- PMLiVE

India turns down patent on Gilead’s Sovaldi

Opens market to cheaper rivals for hepatitis C drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links